Skip to main content Back to Top
Advertisement

12/4/2019

Lidocaine with Epinephrine Injection

Products Affected - Description

    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 1%, 30 mL vial, 100 count, NDC 00409-3178-02
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 1%, 50 mL vial, 100 count, NDC 00409-3178-03
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 2%, 20 mL vial, 100 count, NDC 00409-3182-01
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 2%, 30 mL vial, 100 count, NDC 00409-3182-02
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 2%, 50 mL vial, 100 count, NDC 00409-3182-03
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 2%, 20 mL vial, 25 count, NDC 00409-3183-01
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 10 mL vial, 25 count, NDC 63323-0482-17
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 20 mL vial, 25 count, NDC 63323-0482-27
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 50 mL vial, 25 count, NDC 63323-0482-57
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 20 mL vial, 25 count, NDC 63323-0483-27
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 10 mL vial, 25 count, NDC 63323-0487-17
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 30 mL vial, sterile-pack 5 count, NDC 63323-0487-31
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 30 mL vial, 25 count, NDC 63323-0487-37
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1.5%, 30 mL vial, sterile-pack 5 count, NDC 63323-0488-31
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 10 mL vial, 25 count, NDC 63323-0489-17
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 20 mL vial, sterile-pack 5 count, NDC 63323-0489-21
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 20 mL vial, 25 count, NDC 63323-0489-27

Reason for the Shortage

    • Fresenius Kabi has Xylocaine with epinephrine presentations on shortage due to increased demand for the product and manufacturing delays.
    • Pfizer has lidocaine with epinephrine presentations on shortage due to manufacturing delays.

Available Products

    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 1%, 20 mL vial, 100 count, NDC 00409-3178-01
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 50 mL vial, 100 count, NDC 00409-3177-01
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 1.5%, 30 mL vial, 25 count, NDC 00409-3181-01
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 1.5%, 5 mL glass ampule, 10 count, NDC 00409-1209-01
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.5%, 50 mL vial, 25 count, NDC 63323-0481-57
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 50 mL vial, 25 count, NDC 63323-0483-57
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1.5%, 10 mL vial, 25 count, NDC 63323-0488-17
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1.5%, 30 mL vial, 25 count, NDC 63323-0488-37

Estimated Resupply Dates

    • Fresenius Kabi has 1% Xylocaine with epinephrine (1:200,000) 10 mL vials on back order and the company estimates release dates of mid-December 2019. The 1% Xylocaine with epinephrine (1:200,000) 20 mL vials are on back order and the company estimates release dates of late-December 2019. The 1% Xylocaine with epinephrine (1:200,000) 50 mL vials are on back order and the company estimates release dates of late-December 2019 to early-January 2020. The 1% Xylocaine-MPF with epinephrine (1:200,000) 10 mL vials are on back order and the company estimates release dates of late-January 2020. The 1% Xylocaine-MPF with epinephrine (1:200,000) 30 mL vials are on back order and the company estimates release dates of late-December 2019 to early-January 2020. The 1% Xylocaine-MPF with epinephrine (1:200,000) 30 mL vials in sterile packs are on back order and the company cannot estimate a release date. The 1.5% Xylocaine-MPF with epinephrine (1:200,000) 30 mL vials in sterile packs are on back order and the company cannot estimate a release date. The 2% Xylocaine with epinephrine (1:200,000) 20 mL vials are on back order and the company estimates a release date of late-December 2019 to early-January 2020. The 2% Xylocaine-MPF with epinephrine (1:200,000) 10 mL vials are on back order and the company estimates a release date of early-January 2020. The 2% Xylocaine-MPF with epinephrine (1:200,000) 20 mL vials are on back order and the company estimates a release date of late-January 2020. The 2% Xylocaine-MPF with epinephrine (1:200,000) 20 mL vials in sterile packs are on back order and the company cannot estimate a release date. Check wholesalers for inventory.
    • Pfizer has 1% lidocaine with epinephrine (1:100,000) 30 mL vials available in limited supply. The 1% lidocaine with epinephrine (1:100,000) 50 mL vials are available in limited supply. The 2% lidocaine with epinephrine (1:100,000) 20 mL vials are on back order and the company estimates a release date of December 2019. The 2% lidocaine with epinephrine (1:100,000) 30 mL vials are on back order and the company estimates a release date of December 2019. The 2% lidocaine with epinephrine (1:100,000) 50 mL vials are available in limited supply. The 2% lidocaine with epinephrine (1:200,000) 20 mL vials are on back order and the company estimates a release date of December 2019.

Updated

Updated December 4, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 16, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins